Financial reports
10-K
2023 FY
Annual report
1 Apr 24
10-Q
2023 Q3
Quarterly report
14 Nov 23
10-Q
2023 Q2
Quarterly report
14 Aug 23
ARS
2022 FY
Annual report to shareholders
30 Jun 23
10-Q
2023 Q1
Quarterly report
15 May 23
10-K
2022 FY
Annual report
31 Mar 23
10-Q
2022 Q3
Quarterly report
10 Nov 22
10-Q
2022 Q2
Quarterly report
15 Aug 22
10-Q
2022 Q1
Quarterly report
16 May 22
10-K
2021 FY
Annual report
31 Mar 22
Current reports
8-K
Departure of Directors or Certain Officers
18 Apr 24
8-K
Entry into a Material Definitive Agreement
8 Apr 24
8-K/A
Amendments to Articles of Incorporation or Bylaws
26 Mar 24
8-K
Entry into a Material Definitive Agreement
7 Mar 24
8-K
Regulation FD Disclosure
5 Mar 24
8-K
MyMD Pharmaceuticals Announces Reverse Stock Split to Maintain Nasdaq Listing
13 Feb 24
8-K
Regulation FD Disclosure
6 Dec 23
8-K
MyMD Announces Preclinical Study Results Showing Novel Cannabidiol Analog, Supera-CBD™, Reduced
19 Oct 23
8-K
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
13 Oct 23
8-K
MyMD Pharmaceuticals to Present Updated Statistically Significant Phase 2 Data for MYMD-1, Potential TNF-α Market Disrupter, at BioFuture 2023
4 Oct 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
23 Feb 23
D
$7.41M in options / securities to be acquired, 8 investors
30 Aug 22
424B5
Prospectus supplement for primary offering
17 Aug 22
S-8
Registration of securities for employees
5 Jul 22
424B3
Prospectus supplement
11 May 21
S-3/A
Shelf registration (amended)
28 Apr 21
425
Business combination disclosure
13 Apr 21
425
Business combination disclosure
12 Apr 21
S-3
Shelf registration
25 Mar 21
424B3
Prospectus supplement
23 Mar 21
Proxies
DEFA14A
Additional proxy soliciting materials
21 Jul 23
DEF 14A
Definitive proxy
30 Jun 23
PRE 14A
Preliminary proxy
20 Jun 23
DEFA14A
Additional proxy soliciting materials
22 Mar 23
DEF 14A
Definitive proxy
13 Mar 23
PRE 14A
Preliminary proxy
3 Mar 23
DEFA14A
Additional proxy soliciting materials
26 Oct 22
DEF 14A
Definitive proxy
26 Oct 22
DEFA14A
Additional proxy soliciting materials
13 Dec 21
DEFA14A
Additional proxy soliciting materials
3 Dec 21
Other
EFFECT
Notice of effectiveness
12 May 21
CORRESP
Correspondence with SEC
10 May 21
CORRESP
Correspondence with SEC
28 Apr 21
UPLOAD
Letter from SEC
16 Apr 21
EFFECT
Notice of effectiveness
24 Mar 21
CORRESP
Correspondence with SEC
19 Mar 21
UPLOAD
Letter from SEC
22 Jan 21
EFFECT
Notice of effectiveness
26 Aug 20
CORRESP
Correspondence with SEC
24 Aug 20
UPLOAD
Letter from SEC
21 Aug 20
Ownership
SC 13G
Global X Management CO LLC
14 Feb 24
SC 13G/A
Iroquois Capital Management, LLC
14 Feb 24
4
Paul Rivard
24 Aug 23
4
Paul Rivard
18 Aug 23
4
Christopher C Chapman JR
9 Jun 23
4
Adam Kaplin
9 Jun 23
4
Jude Uzonwanne
9 Jun 23
4
Christopher C Schreiber
9 Jun 23
4
Joshua Silverman
9 Jun 23
4
CRAIG EAGLE
9 Jun 23